Malbork

• A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending
  2025-522831-33-00 4 Hidradenitis Suppurativa
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 5 2024-06-07 Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 5 2025-12-08 Hypertriglyceridemia (HTG)
• A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa Recruiting
  2024-519736-17-00 4 2025-10-03 Hidradenitis Suppurativa
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2024-517513-32-00 5 2025-05-16 Sjögren’s Syndrome
• A Study Evaluating BFB759 in Atopic Dermatitis Ended recruitment
  2025-521624-30-00 4 2026-01-08 Atopic dermatitis
• Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended recruitment
  2024-515672-12-00 5 2025-05-27 Moderate to Severe Genital Psoriasis
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended recruitment
  2023-509301-80-00 5 2024-11-04 Severe hypertriglyceridemia (SHTG)
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended recruitment
  2023-509302-30-00 5 2024-11-04 Hypertriglyceridemia
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended recruitment
  2023-503923-24-00 5 2024-07-22 Sjögren’s Syndrome With Moderate-toSevere Symptom State
• A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended recruitment
  2023-505608-43-00 4 2024-07-04 Moderate to Severe Hidradenitis Suppurativa
• Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended recruitment
  2023-504443-13-00 5 2024-01-29 moderate to severe atopic dermatitis
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin … Ended recruitment
  2023-505695-30-00 5 2021-11-30 systemic lupus erythematosus
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• A Prospective Real-World Evidence Study evaluating the effects of Voltaren use on Mobility and QoL of subjects with knee osteoarthritis (OA) … Ended
  2024-510839-22-00 11 2024-07-18 Mild/non-serious osteoarthritis (OA) of the knee.
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• Study to investigate the efficacy of chaste tree (Vitex agnus-castus BNO 1095 (20 mg)) in women with cramping pain in the lower abdomen occu … Ended
  2023-503688-41-00 5 2023-11-28 Primary Dysmenorrhea
• A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended
  2022-502778-18-00 5 2023-11-17 ulcerative colitis
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label E … Ended
  2022-502827-23-00 4 2023-10-12 Chronic Hand Eczema
• BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended
  2024-514764-72-00 5 2023-09-27 Chronic Urticaria

Showing 1–24 of 31 trials